Several clinical randomized phase III trials have demonstrated that EGFR-mutant advanced NSCLC patients treated with EGFR-TKIs obtain a longer progression-free survival (PFS) than those treated with platinum-based chemotherapy [2–7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.